Oncolytics Biotech Launches Trial of Pelareorep/Atezolizumab Combo in Difficult-to-Treat GI Cancers
OncLive,
Oncolytics Biotech and Roche are launching a new study for multi-indication gastrointestinal (GI) cancer in Germany.
Oncolytics Biotech and Roche are launching a new study for multi-indication gastrointestinal (GI) cancer in Germany.
/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnew…
ONCOLYTICS BIOTECH Aktionäre handeln die Aktien von ONCOLYTICS BIOTECH für einmalig nur 4 Euro HIER GRATIS ANSCHAUEN PR…